Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study

Table 2 Summary statistics of decreases from baseline in cerebrospinal fluid Aβ _1–42 following administration of GSK933776 ^a

Sampling time (h)	GSK933776 (n = 6/dose)	Baseline^b	Postdosing	Change (%)	95% CI
0 to 4	1 mg/kg	363.4 ± 60.1	350.2 ± 61.7	−3.6	(−10.8 to 3.6)
	3 mg/kg	479.2 ± 65.8	446.4 ± 70.8	−6.8	(−14.9 to 1.2)
	6 mg/kg	502.7 ± 71.1	456.1 ± 88.9	−9.7	(−15.4 to −3.9)
5 to 12	1 mg/kg	363.4 ± 60.1	333.9 ± 52.1	−7.9	(−12.6 to −3.2)
	3 mg/kg	479.2 ± 65.8	428.9 ± 77.1	−10.7	(−20.2 to −1.2)
	6 mg/kg	502.7 ± 71.1	433.5 ± 85.1	−14.2	(−19.8 to −8.6)
0 to 12	1 mg/kg	363.4 ± 60.1	340.6 ± 55.7	−6.2	(−11.2 to −1.1)
	3 mg/kg	479.2 ± 65.8	435.7 ± 74.4	−9.2	(−17.9 to −0.5)
	6 mg/kg	502.7 ± 71.1	442.2 ± 86.4	−12.5	(−18.0 to −7.0)

^aCI: confidence interval. Results are reported as means ± standard deviations. ^b-6 to −1 hours predosing.